Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Posted by ZS Editors on Aug 30, 2017 8:00:00 AM

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More

Oncology Biosimilars Outlook: How Key Stakeholders Can Plan for Change

Posted by ZS Editors on Jul 24, 2017 1:04:28 PM

With the oncology biosimilars market poised for expansion, ZS launched an effort to survey the landscape. Our 2017 Biosimilar Adoption Study polled 252 respondents—including 200 oncologists, 25 payers and 27 pharmacy directors—and the results provide a perspective on market perceptions and other factors that could drive or restrict oncology biosimilars’ adoption. 


>
Read More